CAS: 51833-78-4; Angiotensin (1-7)

上下游产品

CAS号4474-91-3 血管紧张素II

📜血管紧张素ii置于angiotensin Converting Enzyme 2,Zinc(II) Chloride体系中,化学反应生成 天冬氨酰-精氨酰-缬氨酰-酪氨酰-异亮氨酰-组氨酰-脯氨酸
参考文献:Nanokit 耦合电喷雾电离质谱分析单个活细胞中血管紧张素转换酶 2 的活性
标题:Nanokit 耦合电喷雾电离质谱分析单个活细胞中血管紧张素转换酶 2 的活性
摘要:血管紧张素转换酶2(ace2)不仅是一种酶,也是严重急性呼吸综合征冠状病毒2(sars-Cov-2)细胞膜上的功能受体.在这里,首先使用 Nanokit 耦合电喷雾电离质谱 (Nanokit-Esi-Ms) 测定单个活细胞中 Ace2 的活性.将微毛细管插入活的 Hace2-Cho 细胞并对细胞质进行电化学分选后,目标 Ace2 酶会水解毛细管内的血管紧张素 Ii,反应生成血管紧张素 1-7.将混合物电喷雾到毛细管尖端后,产物与底物在分子量上进行区分,从而实现单细胞中ace2活性的检测.进一步的测量表明细胞的炎症状态并没有导致ace2催化活性的显着变化,这在单细胞水平上阐明了细胞内ace2活性与炎症之间的关系.所建立的策略将为进一步研究ace2在病毒感染过程中的作用提供具体的分析方法,并扩展基于纳米试剂盒的单细胞分析的应用.
DOI:10.1016/j.Cclet.2022.05.036

专利信息

专利号:US-2004033532-A1
优先权日:2002-08-08
标题 :Use of three-dimensional crystal structure coordinates to design and synthesize domain-selective inhibitors for angiotensin-converting enzyme (ACE)
发明人：EHLERS MARIO R W; HOLMQUIST BARTON
摘要:It has now been discovered that the use of the three-dimensional crystal structure coordinates of angiotensin-converting enzyme (ACE) will enable the design and synthesis, by means of computational chemistry and structure-guided drug design, of inhibitors of ACE that are highly selective and specific for either the N domain or the C domain of the enzyme, for the treatment of diverse diseases. The invention also relates to methods and processes for the structure-guided design and synthesis of dual N- and C-domain ACE inhibitors, and inhibitors that operate by competitive, non-competitive, uncompetitive, and irreversible mechanisms.

专利号:US-7951834-B2
优先权日:2005-05-27
标题 :Angiotensin I-converting enzyme (ACE) inhibitors
发明人：STURROCK EDWARD; NCHINDA ALOYSIUS; CHIBALE KELLY
权利人:UNIV CAPE TOWN
摘要:This invention relates to a process for the synthesis of ketomethylene derivatives of the tripeptide Phe-Gly-Pro (“keto-ACEâ€?, compound 5 a ) and analogues thereof. The synthesis process proceeds via an α,β-unsaturated keto intermediate. A key feature of the process involves a Horner-Emmons olefination of the, -unsaturated keto-phosphonate with ethyl glyoxylate. Keto-ACE analogues produced by the process of the invention display C-domain selectivity.